Skolnik P, Wang M, Rota T, Krane S, Hirsch M; International Conference on AIDS.
Int Conf AIDS. 1989 Jun 4-9; 5: 619 (abstract no. Th.C.P.13).
New England Medical Center, Tufts University, Medford, MA, USA
OBJECTIVE: To determine whether 1,25D alters HIV-1 replication in-vitro. METHODS: A3.5 cells (a monocyte cell line) were treated with 1,25D either before (Pre-Rx) or simultaneously with (Sim-Rx) the addition of HTLV-IIIB. Cultures were assayed for HIV-1 p24 antigen production by ELISA; virus yield assays were also performed (expressed as TCID50/ml). 1,25D (10 ng/ml) modulation of CD4 and HLA-DR expression was analyzed by staining with OKT4 and OKDR-FITC conjugates. Cultures of peripheral blood mononuclear cells (PBMC) from HIV-1 seropositive subjects were performed in the presence or absence of 1,25D (10 ng/ml) by cocultivation with PHA-P stimulated PBMC from seronegative donors and subsequent analysis for HIV-1 p24 antigen production. RESULTS: 1,25D Pre-Rx of HIV-1 infected A3.5 cells increased p24 antigen production and virus yield on assay day 10 as follows: TABULAR DATA, SEE ABSTRACT VOLUME. Similar results were obtained on other assay days and with Sim-Rx cells. 1,25D did not decrease cell number or viability. 1,25D did not alter CD4 or HLA-DR membrane expression. p24 antigen in 1,25D-treated PBMC cultures from 2 of 4 HIV-1 infected subjects was increased 10-fold compared with controls. CONCLUSIONS: 1,25D enhancement of HIV-1 replication may be important for improved HIV isolation from clinical samples and treatment of HIV infection.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antigens, CD4
- Cell Line
- DNA Replication
- HIV
- HIV Antibodies
- HIV Antigens
- HIV Core Protein p24
- HIV Infections
- HIV Seronegativity
- HIV Seropositivity
- HIV-1
- HLA-DR Antigens
- Monocytes
- genetics
- immunology
Other ID:
UI: 102179168
From Meeting Abstracts